title: Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
abstract: BACKGROUND
  Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI). The drawback of clopidogrel treatment is large interindividual variability in response.
  
  
  OBJECTIVE
  Our article aims to suggesting the most convenient method in monitoring the DAPT of post-PCI patients.
  
  
  METHODS
  We analyzed the on-treatment platelet reactivity by light transmission aggregometry and vasodilator-stimulated phosphoprotein (VASP) flow cytometric assay. Samples were obtained in 3 intervals: first prior to PCI, then 1, and 30 days after PCI.
  
  
  RESULTS
  Based on VASP-platelet reactivity index (PRI), we observed 100% response rate in prasugrel-treated patients and 62% to 73 % in the clopidogrel group. Overall, only 2 (7%) patients with the VASP-PRI value in therapeutic range had major adverse cardiovascular events.
  
  
  CONCLUSIONS
  Our results hint VASP-phosphorylation assay as a relevant method for guiding and tailoring DAPT.
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia mfedor@unm.sk.
authors.forename: Marian
authors.initials: M
authors.lastname: Fedor
authors.affiliation: Clinic of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: M
authors.initials: M
authors.lastname: Samoš
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: R
authors.initials: R
authors.lastname: Šimonová
authors.affiliation: Hemo-Medika s.r.o., Centre of Hemostasis and Thrombosis, Martin, Slovakia.
authors.forename: J
authors.initials: J
authors.lastname: Fedorová
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: I
authors.initials: I
authors.lastname: Škorňová
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: L
authors.initials: L
authors.lastname: Duraj
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: J
authors.initials: J
authors.lastname: Staško
authors.affiliation: Clinic of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: F
authors.initials: F
authors.lastname: Kovář
authors.affiliation: Clinic of Internal Medicine I., Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: M
authors.initials: M
authors.lastname: Mokáň
authors.affiliation: Clinic of Hematology and Blood Transfusion, National Centre of Hemostasis and Thrombosis, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Hospital Martin, Slovakia.
authors.forename: P
authors.initials: P
authors.lastname: Kubisz
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy; D000244:Adenosine Diphosphate; D000368:Aged; D000369:Aged, 80 and over; D001241:Aspirin / Q000008:administration & dosage / Q000493:pharmacokinetics; D001792:Blood Platelets / Q000378:metabolism; D015815:Cell Adhesion Molecules / Q000097:blood*; D000077144:Clopidogrel; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008840:Microfilament Proteins / Q000097:blood*; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D062645:Percutaneous Coronary Intervention; D010750:Phosphoproteins / Q000097:blood*; D015539:Platelet Activation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011446:Prospective Studies; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000098662:Vasodilator-Stimulated Phosphoprotein
chemical_list: D015815:Cell Adhesion Molecules; D008840:Microfilament Proteins; D010750:Phosphoproteins; D010975:Platelet Aggregation Inhibitors; D000098662:Vasodilator-Stimulated Phosphoprotein; D000244:Adenosine Diphosphate; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
keywords: ADP inhibitor therapy; ST-segment elevation myocardial infarction; VASP-P; light transmission aggregometry; platelet reactivity index